BSE Live
Nov 04, 16:01Prev. Close
204.60
Open Price
196.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 04, 15:52Prev. Close
204.72
Open Price
205.68
Bid Price (Qty.)
197.31 (294)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Suven Life Sciences (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -2.16 | -0.37 | -1.13 | -2.84 | -1.78 | |
| Diluted EPS (Rs.) | -2.16 | -0.37 | -1.13 | -2.84 | -1.78 | |
| Cash EPS (Rs.) | -1.89 | -0.07 | -0.62 | -2.19 | -1.44 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 36.66 | 38.77 | 39.14 | 32.74 | 31.56 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 36.66 | 38.77 | 39.14 | 32.74 | 31.56 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 0.31 | 0.54 | 0.62 | 0.81 | 1.06 | |
| PBDIT/Share (Rs.) | -1.89 | -0.45 | -0.88 | -2.15 | -1.79 | |
| PBIT/Share (Rs.) | -2.16 | -0.75 | -1.18 | -2.46 | -2.13 | |
| PBT/Share (Rs.) | -2.16 | -0.41 | -0.92 | -2.49 | -2.20 | |
| Net Profit/Share (Rs.) | -2.16 | -0.37 | -0.92 | -2.49 | -1.78 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | -619.18 | -83.86 | -142.51 | -264.47 | -169.11 | |
| PBIT Margin (%) | -706.64 | -139.47 | -190.83 | -301.56 | -201.35 | |
| PBT Margin (%) | -707.34 | -77.06 | -148.65 | -306.04 | -207.40 | |
| Net Profit Margin (%) | -707.34 | -68.48 | -148.65 | -306.04 | -167.91 | |
| Return on Networth / Equity (%) | -5.88 | -0.94 | -2.35 | -7.61 | -5.63 | |
| Return on Capital Employed (%) | -5.87 | -1.92 | -3.01 | -7.44 | -6.68 | |
| Return on Assets (%) | -5.82 | -0.94 | -2.33 | -7.45 | -5.44 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover Ratio (%) | 0.01 | 0.01 | 0.02 | 0.03 | 3.24 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 7.52 | 51.70 | 53.18 | 9.44 | 10.25 | |
| Quick Ratio (X) | 7.49 | 51.55 | 53.18 | 9.44 | 10.24 | |
| Inventory Turnover Ratio (X) | 14.07 | 0.00 | 0.00 | 0.00 | 95.25 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 2,453.00 | 2,020.75 | 883.05 | 1,345.75 | 857.87 | |
| EV/Net Operating Revenue (X) | 368.55 | 172.82 | 65.22 | 113.62 | 63.65 | |
| EV/EBITDA (X) | -59.52 | -206.06 | -45.77 | -42.96 | -37.64 | |
| MarketCap/Net Operating Revenue (X) | 371.55 | 185.94 | 78.07 | 113.85 | 66.48 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 3.09 | 2.57 | 1.24 | 2.83 | 2.23 | |
| Price/Net Operating Revenue | 371.56 | 185.97 | 78.08 | 113.85 | 66.48 | |
| Earnings Yield | -0.02 | 0.00 | -0.02 | -0.03 | -0.03 |
13.05.2025
Suven Life Sci Standalone March 2025 Net Sales at Rs 1.47 crore, down 38.5% Y-o-Y
28.01.2025
Suven Life Sci Consolidated December 2024 Net Sales at Rs 1.61 crore, down 34.31% Y-o-Y
27.01.2025
Suven Life Sci Standalone December 2024 Net Sales at Rs 1.61 crore, down 34.31% Y-o-Y
08.01.2025
Suven Life shares rise 11% on progress in clinical trial of cognitive disorder drug
13.05.2025
Suven Life Sci Standalone March 2025 Net Sales at Rs 1.47 crore, down 38.5% Y-o-Y
28.01.2025
Suven Life Sci Consolidated December 2024 Net Sales at Rs 1.61 crore, down 34.31% Y-o-Y
27.01.2025
Suven Life Sci Standalone December 2024 Net Sales at Rs 1.61 crore, down 34.31% Y-o-Y
30.10.2024
Suven Life Sci Consolidated September 2024 Net Sales at Rs 2.57 crore, down 15.91% Y-o-Y